SUSAN BLANEY to Imatinib Mesylate
This is a "connection" page, showing publications SUSAN BLANEY has written about Imatinib Mesylate.
Connection Strength
0.127
-
Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004 Apr 01; 10(7):2525-9.
Score: 0.057
-
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009 Jan; 63(2):229-38.
Score: 0.019
-
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Feb; 50(2):254-8.
Score: 0.019
-
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007 Apr; 9(2):145-60.
Score: 0.018
-
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004 Nov 01; 104(9):2655-60.
Score: 0.015